New trial tests which immunotherapy combo best battles melanoma before surgery

NCT ID NCT06794775

Recruiting now Disease control Sponsor: Hildur Helgadottir Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different immunotherapy treatments given before surgery for stage III melanoma that can be removed. One group gets a single drug (PD-1 blocker), the other gets a two-drug combo (PD-1 and CTLA-4 blockers). The combo may work better but also has more side effects. About 128 adults with resectable stage III melanoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA STAGE III

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Karolinska University Hospital
RECRUITING

Stockholm, Sweden

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Sahlgrenska University Hospital
RECRUITING

Gothenburg, Sweden

Contact Phone: •••-•••-•••• Email: •••••@•••••
Skane University Hospital
RECRUITING

Lund, Sweden

Contact Phone: •••-•••-•••• Email: •••••@•••••